UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Meet the Regional Editor

Current cancer therapy reviews, 2023-05, Vol.19 (2), p.83-83

Santini, Daniele

2023

Volltextzugriff (PDF)

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

PloS one, 2015-06, Vol.10 (6), p.e0130142-e0130142

2015

Volltextzugriff (PDF)

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

Journal of experimental & clinical cancer research, 2020-05, Vol.39 (1), p.95-95, Article 95

2020

Volltextzugriff (PDF)

Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis

Scientific reports, 2017-08, Vol.7 (1), p.8965-9, Article 8965

2017

Volltextzugriff (PDF)

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis

PloS one, 2015-07, Vol.10 (7), p.e0133488-e0133488

2015

Volltextzugriff (PDF)

Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions

Oncogene, 2021-02, Vol.40 (7), p.1284-1299

2021

Volltextzugriff (PDF)

Hospital admission of cancer patients: avoidable practice or necessary care?

PloS one, 2015-03, Vol.10 (3), p.e0120827-e0120827

2015

Volltextzugriff (PDF)

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors

Therapeutic Advances in Medical Oncology, 2019, Vol.11, p.1758835919890285-1758835919890285

2019

Volltextzugriff (PDF)

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications

JNCI : Journal of the National Cancer Institute, 2022-02, Vol.114 (2), p.271-279

2022

Volltextzugriff (PDF)

Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain

Journal of clinical oncology, 2016-02, Vol.34 (5), p.436-442

2016

Volltextzugriff (PDF)

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

European journal of cancer (1990), 2020-03, Vol.128, p.17-26

2020

Volltextzugriff (PDF)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.57-57, Article 57

2019

Volltextzugriff (PDF)

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial

PloS one, 2017-06, Vol.12 (6), p.e0173593

2017

Volltextzugriff (PDF)

Financial distress in patients with advanced cancer

PloS one, 2017-05, Vol.12 (5), p.e0176470-e0176470

2017

Volltextzugriff (PDF)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

PloS one, 2017-05, Vol.12 (5), p.e0177331-e0177331

2017

Volltextzugriff (PDF)

The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide

Cancer treatment reviews, 2017-04, Vol.55, p.71-82

2017

Volltextzugriff (PDF)

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

The lancet oncology, 2013-06, Vol.14 (7), p.663-670

2013

Volltextzugriff (PDF)

Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR‐TKIs and mTOR inhibitor

International journal of cancer, 2014-06, Vol.134 (12), p.2772-2777

2014

Volltextzugriff (PDF)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Journal for immunotherapy of cancer, 2020-11, Vol.8 (2), p.e001361

2020

Volltextzugriff (PDF)

Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer

Scientific reports, 2020-01, Vol.10 (1), p.1288, Article 1288

2020

Volltextzugriff (PDF)

Emerging concepts on drug resistance in bladder cancer: Implications for future strategies

Critical reviews in oncology/hematology, 2015-10, Vol.96 (1), p.81-90

2015

Volltextzugriff (PDF)

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2009-06, Vol.27 (16), p.2622-2629

2009

Volltextzugriff (PDF)

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients

PloS one, 2015-06, Vol.10 (6), p.e0128368-e0128368

2015

Volltextzugriff (PDF)

Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study

The lancet oncology, 2012-10, Vol.13 (10), p.1020-1024

2012

Volltextzugriff (PDF)

1 – 25 von 1.011

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(920)
Mit Volltextzugriff
(871)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Free E-Journal (出版社公開部分のみ）
(553)
MEDLINE
(524)
Ingenta
(437)
Journals@Ovid Full Text
(332)
Single Journals
(229)
IngentaConnect Journals
(216)
Elsevier ScienceDirect Journals Complete
(140)
2022 ECC(Springer)
(106)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(103)
Taylor & Francis
(92)
Taylor & Francis Journals
(88)
Wiley-Blackwell Journals
(79)
Taylor & Francis Journals Complete
(67)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(59)
Wiley Online Library
(51)
Nature_系列刊
(32)
Nexis Uni
(26)
SAGE Publications
(20)
SpringerLink Series
(17)
Oxford Journals
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(108)
Plos One
(43)
Critical Reviews In Oncology/hematology
(25)
Oncotarget
(22)
European Journal Of Cancer
(18)
Blood
(17)
Expert Opinion On Biological Therapy
(16)
Cancers
(14)
Frontiers In Oncology
(13)
Cancer Treatment Reviews
(12)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Meet the Regional Editor

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis

Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions

Hospital admission of cancer patients: avoidable practice or necessary care?

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications

Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial

Financial distress in patients with advanced cancer

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR‐TKIs and mTOR inhibitor

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer

Emerging concepts on drug resistance in bladder cancer: Implications for future strategies

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients

Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study

Suchergebnisse filtern